Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EMD Millipore Launches New Kits for Use on Gyros’ Immunoassay Platform

Published: Wednesday, March 26, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Ready-to-use kits are fully qualified for reliable use in clinical research.

Gyros AB has announced that EMD Millipore, Life Science division of Merck KGaA of Darmstadt, Germany, has released five new immunoassay kits designed specifically for use on Gyrolab™ xP workstation.

The new, fully qualified GyroMark™ HT kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 480 data points can be generated in a run.

“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1.

EMD Millipore plans to release additional kits this year and is offering custom kits for companies who have specific needs or unique or novel antibodies.

Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays provide:

• accuracy over a four-log dynamic range (compared to two logs for ELISAs)
• elimination of cross-talk and plate position artifacts
• simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference

Gyros’ Global Marketing Director Maria Hjortsmark commented: “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros and Tekon Biotech Sign Distribution Agreement
Tekon will distribute Gyros’ immunoassay platform in China, Taiwan & Hong Kong.
Tuesday, April 01, 2014
Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
Gyros AB announced that BioAgilytix Labs has invested in two Gyrolab™ xP workstations to support its bioanalysis services.
Tuesday, November 12, 2013
Dan Calvo Appointed CEO of Gyros AB
Erik Walldén steps down as chief executive officer and president.
Thursday, October 24, 2013
Gyros AB Quality Management System Receives ISO 9001:2008 Certification
Certification reassures customers that they receive consistently high standard of products and services.
Tuesday, December 18, 2012
Gyros Expands Asian Distribution to Singapore
Nanoliter-scale immunoassay platform now available to biopharmaceutical companies in Singapore region.
Thursday, June 07, 2012
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
Gyros AB announces that GE Healthcare Life Sciences has become the sole distributor for the company’s nanoliter-scale immunoassay platform in Japan.
Tuesday, July 12, 2011
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!